Literature DB >> 25403223

Reply to N.-K.V. Cheung et al.

Katherine K Matthay1, Wendy B London2, John Maris3, Peter C Adamson3, Julie R Park4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25403223      PMCID： PMC5142206          DOI： 10.1200/JCO.2014.58.7006

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

Review 1.  Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.

Authors:  William Clay Gustafson; Katherine K Matthay
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

2.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?

Authors:  Nai-Kong V Cheung; Shakeel Modak; Irina Ostrovnaya; Stephen S Roberts; Ellen M Basu; Kim Kramer; Brian H Kushner
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

4.  Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

Authors:  Frank Berthold; Joachim Boos; Stefan Burdach; Rudolf Erttmann; Günter Henze; Johann Hermann; Thomas Klingebiel; Bernhard Kremens; Freimut H Schilling; Martin Schrappe; Thorsten Simon; Barbara Hero
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

5.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Authors:  K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

6.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

7.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Authors:  Susan G Kreissman; Robert C Seeger; Katherine K Matthay; Wendy B London; Richard Sposto; Stephan A Grupp; Daphne A Haas-Kogan; Michael P Laquaglia; Alice L Yu; Lisa Diller; Allen Buxton; Julie R Park; Susan L Cohn; John M Maris; C Patrick Reynolds; Judith G Villablanca
Journal:  Lancet Oncol       Date:  2013-07-25       Impact factor: 41.316

8.  High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Authors:  Jon Pritchard; Simon J Cotterill; Shirley M Germond; John Imeson; Jan de Kraker; David R Jones
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167
  8 in total
  2 in total

1.  Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.

Authors:  C Pasqualini; C Dufour; G Goma; M-A Raquin; V Lapierre; D Valteau-Couanet
Journal:  Bone Marrow Transplant       Date:  2015-11-02       Impact factor: 5.483

2.  Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

Authors:  Frank Berthold; Angela Ernst; Barbara Hero; Thomas Klingebiel; Bernhard Kremens; Freimut H Schilling; Thorsten Simon
Journal:  Br J Cancer       Date:  2018-07-11       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.